Recent studies have highlighted a potentially important role for Wnts as profibrotic mediators, and implicated increased Wnt activity in systemic sclerosis and other fibrotic diseases. Strikingly, new data indicates that Wnts have a central role in the profibrotic activity of TGF-β.
Systemic sclerosis (SSc) is a multiorgan, fibro tic autoimmune disease that is also known as scleroderma. The fibrotic fea tures of SSc are currently untreatable, lead ing to considerable morbidity and mor tality, making new therapeutic agents for this disease of particular importance. Wnts, known for their wideranging roles dur ing development, have been increasingly inves tigated in disease processes. Now, their pos sible role in fibrosis has been highlighted by a new study by Akhmetshina et al., 1 the find ings of which add to the growing litera ture des cribing Wnt activity in SSc and highlight Wnts as future therapeutic targets.
Using a transgenic mouse overexpress ing Dickkopfrelated protein 1 (DKK1), an endo genous Wnt inhibitor, Akhmetshina et al. 1 showed that blocking Wnt proteins inhibits skin fibrosis in several mouse models of SSc; DKK1 blocked fibrosis in Tsk1 mice (characterized by progres sive col lagen and hypodermal thickening), bleomycininduced skin fibrosis in mice and a novel murine model of skin fibro sis induced by sub cutaneous injection of an adeno viruses expressing transform ing growth factor (TGF)β receptor 1. Further more, the researchers provide an intriguing link between Wnt and TGFβ, the profibrotic mediator most strongly implicated in SSc as well as other fibrotic diseases. They show that, in dermal fibro blasts, TGFβ inhibits DKK1 expression, whilst inducing intranuclear expression of βcatenin and axin2, cellular events typi cally provoked by Wnt activation. These observations suggest that the profibrotic effect of TGFβ is mediated by endogenous Wnt activity, as revealed by downregula tion of DKK1 in this setting. Completing this picture, recombinant DKK1 added to TGFβtreated fibroblasts blocked the profibrotic effects of TGFβ.
1 These data, together with the results of DKK1 in murine models, underline the wellestablished balance between Wnts and Wnt inhibitors in determining Wnt activity. This balance has been clearly shown in developmental settings; for example, in regulating hair follicle development and spacing. In addi tion, Wnt and TGFβ pathways have been shown to intersect both through coregula tion of promoters and through binding to SMAD4 and LEF, indicating that these two molecules form a complex that affects downstream signal ling, an interaction that signals formation of Spemann's organizer (a dorsal signalling centre). 2 The notion that Wnts might be pro fibro tic is consistent with several other exist ing observations. Our group showed several years ago that Wnt3, another canoni cal Wnt, stimulates connective tissue growth factor (CTGF) and smooth muscle actin, a marker for myofibrobalsts. 3 Moreover, Wei et al. 4 have more recently shown that transgenic mice overexpressing Wntb10b develop skin fibrosis and lipo atrophy. These authors suggest that the effect of Wnts in skin, particularly Wnt10b, might be related to its developmental role in shift ing fibroblast differentiation away from an adipogenic to profibrotic phenotype. Such a mechanism is reminiscent of early studies showing that Wnts control muscle stem cells in aging, pushing them toward a more fibrogenic pheno type. 5 This finding is re inforced in a more recent report by the same group showing that Wnt3a stimulates a shift in preadipocytes from adipocyte to myo fibroblast differentiation. 6 The effect is mediated, at least in part, by TGFβ acti vation of SMAD2/3 phos phorylation and Wnt inhibi tion of peroxisome proliferator activated receptor γ.
Wei and colleagues 4 also showed that Wnt10b stimulates fibrosis in a mouse model of SSc independently of TGFβ. This finding is consistent with the new report by Akhmetshina and coworkers, 1 which showed that TGFβ is effectively permis sive to the effects of apparently endo genous Wnt(s) by downregulating DKK1. The source of this Wnt activity in fibroblast cul tures in unclear, but might be produced by the fibroblasts themselves or be present in the serum used for fibroblast culture.
Interestingly, other cytokines have pre viously been implicated in mediating the profibrotic effects of TGFβ, namely CTGF and endothelin1. Although it might seem implausible that all these mediators (Wnt, endothelin1 and CTGF) are required for the profibrotic activity of TGFβ, per haps regulation of fibrosis is so tightly con trolled that multiple factors-that is a 'per fect storm'-is required to permit progres sive TGFβmediated fibrosis. Alterna tively, Wnts could be part of a heretofore unrecog nized cytokine cascade triggered by TGFβ. 
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Turning back to the effect of Wnt inhibi tion described by Akhmetshina et al. 1 in murine models, the in vitro activity of DKK1 suggests that its overexpression in vivo is blocking a profibrotic Wnt signal, not neces sarily requiring the involvement of TGFβ. The results are in agreement with another report showing that Wnt10b is upregulated in bleomycininduced mouse models of skin fibrosis. 4 The results reported here are also largely in agreement with our previous observations that fascial hypertrophy seen in Tsk1 mice, starting during late embryogenesis, is associated with striking upregulation of several Wnts including Wnt2 and Wnt11, though with only mo destly increased Wnt10b expres sion. 7 1 demonstrated increased expres sion of Wnt1 and Wnt10b, and decreased expression of DKK1, in skin from patients with SSc. How ever, the unknown status of the plethora of other Wnts and endogenous Wnt inhibitors complicates interpretation of these findings. Myself and others have pre viously reported in a comprehensive survey of Wnt mRNA levels in the skin of patients with SSc that only Wnt2 was statistically sig nificantly upregulated (by a modest average increase of 2.2fold compared with healthy controls).
3 By contrast, the Wnt inhibitor, secreted frizzledrelated protein 4 (SFRP4), was also strongly upregulated whereas DKK1 showed no change in expression and WIF1 (Wnt inhibitory factor 1, another Wnt inhibitor) was downregualted 7.9fold. 3 Thus, our data strongly implicate WIF1, rather than DKK1, in potentially permit ting unrestrained Wnt activity in the skin of patients with SSc. On the other hand, consistent with the current report, Wei et al. 4 have also shown the Wnt10b protein is upregulated in the skin of an SSc mouse model. Differences between mRNA and protein levels could explain the differ ences in these studies, but the ambiguities associ ated with immuno histochemical studies should provide some pause for thought regarding the specific Wnt(s) and Wnt inhibitors regulated in SSc skin.
Assessing cytokine activity in human pathology is difficult and continues to 'plague' most human studies; it is particu larly important for research into the effects of Wnts, owing to the large number of Wnts and Wnt antagonists. In the report by Akhmetshina et al., 1 increased levels of nuclear βcatenin staining supports upregulated Wnt activity in SSc skin, which has also been seen in lungs from patients with SSc. 9 Cytokineregulated genes pro vide another means to try and implicate a cytokine in pathogenesis and have been applied in SSc to infer a role for interferon and TGFβ activity in SSc. 10 Increased AXIN2 expression in SSc skin supports Wnt activation occurring here, but provides a narrow 'signature' for the effect of Wnt. My colleagues and I previously reported a modest, but statistically significant, increase in Wnt activity in sera from patients with SSc compared with healthy controls, further supporting the notion that increased Wnt activity could contribute to SSc fibrosis. 3 An improved understanding of the role of Wnts in mediating the effect of TGFβ on fibrosis is crucial for considering the possibility of therapeutic intervention. If blocking Wnt activity is able to inhibit the profibrotic activity of TGFβ, then this approach becomes an attractive target for intervention in SSc. Global blockade of Wnt activity would clearly be harmful during development, but might be tolerated in adults. However, a more complete under standing of the specific defects involving Wnts and/or endogenous Wnt inhibitors in SSc would potentially permit more selec tive approaches to therapy targeting the Wnt pathway. 
